Loading…
avatar for Hans Lehrach

Hans Lehrach

Hans Lehrach obtained his Ph.D. at the Max Planck Institute for Experimental Medicine and the Max Planck Institute for Biophysical Chemistry in 1974. Next he moved on to Harvard University, Boston (1974-1978) for a postdoc and then became group leader at EMBL, Heidelberg (1978-1987). He then moved to the Imperial Cancer Research Fund, London (1987-1994) to become head of the Genome Analysis Department. In 1994 he returned to Germany to become Director and Scientific Member at the Max Planck Institute for Molecular Genetics (since 1994).

His scientific achievements are many. Highlights include his key involvement in several genome sequencing projects, such as the human, rat, and Schizosaccharomyces. His group also was part of the team which identified the Huntington’s disease gene. Hans Lehrach also performed key work on technologies such as protein microarrays, protein interactome analysis, yeast artificial chromosomes and RNAseq. For his work, Dr. Lehrach has received several awards such as the Ján Jessenius SAS Medal of Honour for outstanding achievements in medical sciences of the Slovak Academy of Sciences and the Karl Heinz Beckurts Award for achievements in genome research.

Hans Lehrach has co-founded several biotechnology companies such as Sequana Therapeutics, GPC Biotech, Scienion, Prot@gen, PSF Biotech, Atlas Biolabs, Alacris Theranostics, as well as the Dahlem Centre for Genome Research and Medical Systems Biology gGmbH (DCGMS).